Rennie Dual Action Chewable Tablets Calcium carbonate 625mg Magnesium carbonate 73.5mg Alginic acid 150mg

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Alginic acid; Calcium carbonate; Magnesium carbonate

Available from:

Bayer Limited

ATC code:

A02AD

INN (International Name):

Alginic acid; Calcium carbonate; Magnesium carbonate

Dosage:

625/73.5/150 milligram(s)

Pharmaceutical form:

Chewable tablet

Prescription type:

Product not subject to medical prescription

Therapeutic area:

Combinations and complexes of aluminium, calcium and magnesium compounds

Authorization status:

Not marketed

Authorization date:

2009-02-06

Patient Information leaflet

BCH22023
1/5
PACKAGE LEAFLET: INFORMATION FOR THE USER
RENNIE DUAL ACTION TABLETS
Calcium carbonate, Magnesium carbonate, Alginic acid
Chewable tablets
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT
CONTAINS IMPORTANT INFORMATION FOR YOU.
Always take this medicine exactly as described in this leaflet or as
your doctor or
pharmacist has told you.
-
Keep this leaflet. You may need to read it again.
-
Ask your pharmacist if you need more information or advice.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any
possible side effects not listed in this leaflet. See section 4.
-
You must contact a doctor if you do not feel better or if you feel
worse after 14
days.
WHAT IS IN THIS LEAFLET
1.
What Rennie Dual Action Tablets are and what they are used for
2.
What you need to know before you take Rennie Dual Action Tablets
3.
How to take Rennie Dual Action Tablets
4.
Possible side effects
5.
How to store Rennie Dual Action Tablets
6.
Contents of the pack and other information
1.
WHAT RENNIE DUAL ACTION TABLETS ARE AND WHAT THEY ARE
USED FOR
Rennie Dual Action tablets provide relief from heartburn and acid
indigestion.
Rennie Dual Action tablets work in two different ways:
1.
Alginic acid forms a protective barrier in the stomach to stop acid
escaping
upwards, soothing that burning pain in your chest
2.
Calcium carbonate and magnesium carbonate provide rapid and long
lasting
neutralization of excess acid in the stomach
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE RENNIE DUAL
ACTION TABLETS
DO NOT TAKE RENNIE DUAL ACTION TABLETS:
•
If you have severe kidney disease or suffer from kidney stones.
•
If you have high calcium or low phosphate levels in the blood.
•
If you are allergic to any of the ingredients.
BCH22023
2/5
WARNINGS AND PRECAUTIONS:
As with other antacid products, taking these tablets can mask the
symptoms of other,
more serious, underlying medical conditions. If symptoms persist after
fourteen days
consult your doctor.
Patients aged 55 year

Summary of Product characteristics

Health Products Regulatory Authority
10 November 2022
CRN00D61K
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Rennie Dual Action Chewable Tablets Calcium carbonate 625mg Magnesium
carbonate 73.5mg Alginic acid 150mg
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each chewable tablet contains:
Alginic acid 150mg, calcium carbonate 625mg and heavy magnesium
carbonate 73.50mg.
Excipients: each chewable tablet contains 14 mg sodium as well as
sucrose (230 mg) and glucose (555.22 mg).
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Chewable tablet
Off white, speckled circular tablet, flat on both sides with a
bevelled edge.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Symptomatic treatment of complaints resulting from gastro-oesophageal
reflux and hyperacidity, such as regurgitation and
heartburn.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
The usual dose is 2 tablets to be chewed. It should preferably be
taken one hour after meals and before going to bed. An
additional dose can also be taken in between in the case of heartburn.
The maximum dose of 8 grams calcium carbonate
(corresponding to 12 tablets) per day should not be exceeded and
should not be taken continuously for longer than 2 weeks.
Only for use by adults and children over 12 years of age.
As with all antacids, if symptoms persist despite 14 days of
continuous therapy, diagnostic measures are strongly
recommended in order to rule out a more serious disease.
Pregnant women should limit the duration of treatment this medicinal
product is used as symptoms subside, and it should not
be used for more than two weeks.
For Special warning and precautions for use please also see section
4.4.
4.3 CONTRAINDICATIONS

Severe renal insufficiency

Hypercalcaemia and/or conditions resulting in hypercalcaemia

Pre-existing hypophosphataemia

Nephrolithiasis due to calculi containing calcium deposits

Hypersensitivity to the active substances or to any of the excipients
4.4 SPECIAL WARNINGS AND PRECAUTION